Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Omada Health, Inc. (OMDA) SEC Filings & Earnings Calls

EquiReason read 10 Omada Health, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-07 — Omada reported strong Q2 2026 results: revenue +43% YoY, gross margin expanded 7ppt, and the company achieved operating and net income profitability..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

OMDAOmada Health, Inc.Follow OMDA — free
Health Information Services · Healthcare
—
Price chart with a free account
Market cap
1.2B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

7 Aug 202610-QOmada reported strong Q2 2026 results: revenue +43% YoY, gross margin expanded 7ppt, and the company achieved operating and net income profitability.earningsopen

Figures in the filing · each found in the filing text

Total Members · Q2-20261,091,000+45% y/y
Total Revenue · Q2-2026$88M+43% y/y
Services Revenue · Q2-2026$81M+42% y/y
Hardware Revenue · Q2-2026$7M+62% y/y
Gross Profit · Q2-2026$64M+58% y/y
Gross Margin · Q2-202673.0%
Operating Income (Loss) · Q2-2026$4M-182% y/y
Net Income (Loss) · Q2-2026$5M-200% y/y
Cash and Cash Equivalents · Q2-2026$222M
Accumulated Deficit · Q2-2026$454M

Risks flagged

Customer Concentration

“Sales from or through our top five health plan and PBM partners, including any sales to these entities as customers and sales through these entities as channel partners, represented 79% and 76% of our revenue for the three months ended June 30, 2026 and 2025, respectively” · word for word

Tariff and Geopolitical Cost Pressure

“we expect that the prices of these devices may increase as a result of recent tariffs and any new or increased tariffs in the future. In addition, the war in Iran has resulted in modest increases to device-related costs to date due to increased shipping costs.” · word for word

Negative Operating Cash Flow

“Net cash used in operating activities during the six months ended June 30, 2026 of $7.8 million” · word for word

Dependence on Channel Partners

“Partner A and Partner B (affiliates of The Cigna Group) accounted for 31% and 33% of revenue respectively for the three months ended June 30, 2026.”
Read the original on SEC EDGAR ↗
6 Aug 20268-K · 2.02, 5.02CEO Sean Duffy becomes Executive Chairman; President Wei-Li Shao succeeds as CEO effective Jan 1, 2027. Lead Independent Director appointed. No compensation changes yet.open

Risks flagged

Leadership transition risk; CEO change may cause strategic uncertainty until transition completes.

“CEO change effective Jan 1, 2027; no compensation changes yet approved.”
Read the original on SEC EDGAR ↗
8 May 202610-QOmada Health reported strong Q1 2026 results: revenue +42% YoY to $78M, gross margin +440 bps to 62.4%, operating loss narrowed 43%, and members surpassed 1 million.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q1-2026$78M+42% y/y
Services Revenue · Services · Q1-2026$70M+41% y/y
Hardware Revenue · Hardware · Q1-2026$8M+55% y/y
Gross Profit · Q1-2026$49M+53% y/y
Net Loss · Q1-2026$-3M-69% y/y
Cash and Cash Equivalents · 2026-03-31$212M+256% y/y
Total Members · 2026-03-311,025,000
Accumulated Deficit · 2026-03-31$-460M

Risks flagged

Customer concentration risk

“Partner A and Partner B (affiliates of The Cigna Group) accounted for 33% and 33% of revenue for the three months ended March 31, 2026, respectively.”

Dependence on related party

“Includes amounts from a related party of $46.0 million and $29.9 million for services revenue for the three months ended March 31, 2026 and 2025, respectively.” · word for word
Read the original on SEC EDGAR ↗
7 May 20268-K · 2.02Total Members 1,020,000 (+51% y/y); Revenue $78M (+42% y/y); Gross Margin 62; Guidance: Revenue guidance raised from $312M-$322M to $322M-$330M; adjusted EBITDA guidance raised from $7M-$15M to $14M-$20Mearningsopen

Figures in the filing · each found in the filing text

Total Members · Q1-20261,020,000+51% y/y
Revenue · Q1-2026$78M+42% y/y
Gross Margin · Q1-202662.0%
Non-GAAP Gross Margin · Q1-202664.0%
Net Loss · Q1-2026$-3M
Adjusted EBITDA · Q1-2026$1M
Cash and Cash Equivalents · Q1-2026$212M

Guidance

Revenue guidance raised from $312M-$322M to $322M-$330M; adjusted EBITDA guidance raised from $7M-$15M to $14M-$20M

Raised FY2026 revenue and adjusted EBITDA guidance, reflecting strong Q1 performance and confidence in continued growth driven by GLP-1 program and PBM relationships.

Risks flagged

Dependence on GLP-1 drug pricing and reimbursement; regulatory changes could impact demand.

“GLP-1 Care Track and prescribing capabilities are central to growth; drug pricing pressure or reimbursement changes could affect member acquisition and revenue.” · word for word

Limited operating history and history of net losses; path to GAAP profitability uncertain.

“Cautionary note mentions limited operating history and history of net loss; adjusted EBITDA positive but GAAP net loss continues.”
Read the original on SEC EDGAR ↗
28 Apr 2026DEF 14AAnnual proxy statement filed for 2026 annual meeting; no material event disclosed.open

Figures in the filing · each found in the filing text

Revenue from Cigna affiliates · FY2025$158M
Revenue from Cigna affiliates · Q1-2026$58M
Payments to Cigna affiliates for administrative services · FY2025$13M
Payments to Cigna affiliates for administrative services · Q1-2026$4M
Payments to Cigna affiliates for benefits · FY2025$11M
Payments to Cigna affiliates for benefits · Q1-2026$6M
Shares outstanding · 2026-04-2059,415,251
CEO beneficial ownership · 2026-04-203.3%
Insider ownership group · 2026-04-206.4%
CEO total compensation · FY2025$5M

Risks flagged

Customer concentration risk

“Pursuant to the Cigna Group Customer Agreements, affiliates of The Cigna Group made payments to us of $157.6 million in the year ended December 31, 2025 and $58.1 million since January 1, 2026.” · word for word

Key person dependency on CEO

“Sean Duffy has served as our co-founder, Chief Executive Officer, and as a member of our Board since April 2011.” · word for word
Read the original on SEC EDGAR ↗
6 Mar 202610-KNet Loss $-13M (+73% y/y); Accumulated Deficit $457M; Revenue Concentration - Top 5 Partners 77open

Figures in the filing · each found in the filing text

Net Loss · FY2025$-13M+73% y/y
Accumulated Deficit · 2025-12-31$457M
Revenue Concentration - Top 5 Partners · FY202577.0%

Risks flagged

Customer Concentration

“For the year ended December 31, 2025, we had one health plan or PBM that accounted for 32% of our revenue, and a second health plan or PBM that accounted for 33% of our revenue.” · word for word

Accumulated Losses

“As of December 31, 2025, we had an accumulated deficit of $456.7 million.” · word for word

Material Weakness in Internal Controls

“We have identified a material weakness in our internal control over financial reporting.” · word for word

Regulatory Risk - Medicaid/ACA Changes

“In July 2025, the One Big Beautiful Bill Act (the 'OBBBA') was enacted, which imposes significant reductions in the funding of the Medicaid program and restrictions for certain groups to access the ACA Marketplace.” · word for word
Read the original on SEC EDGAR ↗
5 Mar 20268-K · 2.02Total members 886,000 (+55% y/y); Revenue $76M (+58% y/y); Revenue $260M (+53% y/y); Guidance: FY2026 revenue $312-322M (22% growth at midpoint); adjusted EBITDA $7-15Mearningsopen

Figures in the filing · each found in the filing text

Total members · FY2025886,000+55% y/y
Revenue · Q4-2025$76M+58% y/y
Revenue · FY2025$260M+53% y/y
Gross margin · Q4-202571.0%
Non-GAAP gross margin · Q4-202573.0%
Net income (loss) · Q4-2025$5M
Net loss · FY2025$-13M
Adjusted EBITDA · Q4-2025$8M
Adjusted EBITDA · FY2025$6M
Cash and cash equivalents · FY2025$222M

Guidance

FY2026 revenue $312-322M (22% growth at midpoint); adjusted EBITDA $7-15M

Explicit revenue guidance with 22% growth at midpoint; adjusted EBITDA positive; strong member and revenue momentum; margin expansion; positive tone.

Risks flagged

Dependence on GLP-1 market growth and reimbursement

“GLP-1 companion support is a key growth driver; new GLP-1 Flex Care offering shifts financial risk to employers; regulatory and competitive risks in GLP-1 space.”

Profitability still nascent; adjusted EBITDA guidance for FY2026 implies modest margin

“FY2026 adjusted EBITDA guidance $7-15M on $312-322M revenue implies ~2-5% margin; still low relative to revenue scale.”
Read the original on SEC EDGAR ↗
12 Jan 20268-K · 2.02Revenue $257M (+52% y/y); Total members 886,000 (+55% y/y)earningsopen

Figures in the filing · each found in the filing text

Revenue · FY2025$257M+52% y/y
Total members · FY2025886,000+55% y/y

Risks flagged

Preliminary results subject to audit adjustment; concentration risk with limited customers.

“Preliminary and unaudited; risk factors include customer concentration.”
Read the original on SEC EDGAR ↗
7 Nov 202510-QOmada Health reported Q3 2025 revenue of $68.0M (+49% YoY), gross margin expansion to 66.3%, and significantly narrowed net loss to -$3.2M, driven by strong member growth and operational efficiencies.earningsopen

Figures in the filing · each found in the filing text

Total Members · Q3-2025831,000+53% y/y
Revenue · Q3-2025$68M+49% y/y
Services Revenue · Q3-2025$63M+50% y/y
Gross Margin · Q3-202566.3%
Cash and Cash Equivalents · Q3-2025$199M
Free Cash Flow · 9M-2025$-8M
Accumulated Deficit · Q3-2025$-462M
Concentration Revenue Top5 · Q3-202576.0%

Risks flagged

Customer Concentration Risk

“Sales from or through our top five health plan and PBM partners, including any sales to these entities as customers and sales through these entities as channel partners, represented 76% and 70% of our revenue for the three months ended September 30, 2025 and 2024, respectively.” · word for word

Tariff Exposure on Hardware

“Cost of hardware revenue increased by $4.0 million, or 63%, for the three months ended September 30, 2025 compared to the three months ended September 30, 2024, primarily driven by a 53% increase in total members, reflecting new members enrolled in our programs compared to the prior-year period, which drove new devices, supplies, fulfillment costs, which inc” · word for word

History of Net Losses

“We have incurred net losses since our inception, and we may incur net losses in the future. For the three months ended September 30, 2025 and 2024, we incurred net losses of $3.2 million and $9.2 million, respectively.” · word for word
Read the original on SEC EDGAR ↗
6 Nov 20258-K · 2.02Revenue $68M (+49% y/y); Total members 831,000 (+53% y/y); Gross margin 66earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$68M+49% y/y
Total members · Q3-2025831,000+53% y/y
Gross margin · Q3-202566.0%
Net loss · Q3-2025$-3M
Adjusted EBITDA · Q3-2025$2M
Cash and cash equivalents · Q3-2025$199M

Guidance

Raised full-year guidance on strong Q3 performance and positive outlook.

Risks flagged

History of net losses and ability to achieve profitability

“Our history of net losses and ability to achieve or maintain profitability.” · word for word

Dependence on market acceptance of programs

“The ability of our programs to achieve and maintain market acceptance.” · word for word
Read the original on SEC EDGAR ↗

Omada Health, Inc. — questions

What did Omada Health, Inc. file recently?
10 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-07 — Omada reported strong Q2 2026 results: revenue +43% YoY, gross margin expanded 7ppt, and the company achieved operating and net income profitability.

Every figure on this page comes from Omada Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.